止敏吐膠囊125毫克

Quốc gia: Đài Loan

Ngôn ngữ: Tiếng Trung

Nguồn: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Thành phần hoạt chất:

APREPITANT

Sẵn có từ:

美商默沙東藥廠股份有限公司台灣分公司 台北市信義區信義路五段106號12樓 (86683720)

Mã ATC:

A04AD12

Dạng dược phẩm:

膠囊劑

Thành phần:

APREPITANT (9200095800) MG

Các đơn vị trong gói:

鋁箔盒裝

Lớp học:

製　劑

Loại thuốc theo toa:

須由醫師處方使用

Sản xuất bởi:

ALKERMES PHARMA IRELAND LIMITED MONKSLAND ATHLONE CO. WESTMEATH, IRELAND IE

Khu trị liệu:

aprepitant

Chỉ dẫn điều trị:

與其他止吐藥劑併用，可以防止由高致吐性及中致吐性癌症化療藥物在初次或重覆使用時所引起的急性或延遲性噁心與嘔吐。

Tóm tắt sản phẩm:

有效日期: 2024/05/14; 英文品名: EMEND CAPSULES 125MG

Ngày ủy quyền:

2004-05-14

Tờ rơi thông tin

EMEND™ CAPSULES
(APREPITANT)
THERAPEUTIC CLASS
EMEND
*
(aprepitant), is a substance P neurokinin 1 (NK
1
) receptor antagonist.
COMPOSITION
Each capsule of EMEND for oral administration contains either 80 mg,
or 125 mg of aprepitant.
Each capsule of EMEND contains the following inactive ingredients:
sucrose, microcrystalline
cellulose, hydroxypropyl cellulose and sodium lauryl sulfate. The
capsule shell excipients are
gelatin and titanium dioxide, and may contain sodium lauryl sulfate
and silicon dioxide. The 125-
mg capsule shell also contains red ferric oxide and yellow ferric
oxide.
CLINICAL PHARMACOLOGY
_MECHANISM OF ACTION_
Aprepitant has a unique mode of action; it is a selective high
affinity antagonist at human
substance P neurokinin 1 (NK
1
) receptors. Counter-screening assays showed that aprepitant
was at least 3,000-fold selective for the NK
1
receptor over other enzyme, transporter, ion
channel and receptor sites including the dopamine and serotonin
receptors that are targets for
existing chemotherapy induced nausea and vomiting (CINV) therapies.
NK
1
-receptor antagonists have been shown pre-clinically to inhibit emesis
induced by cytotoxic
chemotherapeutic agents, such as cisplatin, via central actions.
Preclinical and human Positron
Emission Tomography (PET) studies with aprepitant have shown that it
is brain penetrant and
occupies brain NK
1
receptors. Preclinical studies show that aprepitant has a long
duration of
central activity, inhibits both the acute and delayed phases of
cisplatin-induced emesis, and
augments
the
antiemetic
activity
of
the
5-HT
3
-receptor
antagonist
ondansetron
and
the
corticosteroid dexamethasone against cisplatin-induced emesis.
_PHARMACOKINETICS _
_ABSORPTION_
The mean absolute oral bioavailability of aprepitant is approximately
60 to 65% and the mean
peak plasma concentration (C
max
) of aprepitant occurred at approximately 4 hours (T
max
). Oral
administration of the capsule with a standard breakfast had no
clinically meaningful effect on the
bioavailability of apr